Role of aspirin in MATCH [1] (multiple letters)

Lancet

Volumn 364, Issue 9446, 2004, Pages 1661-1663

  Ling, Geoffrey S F ^a   Eriksson, Peter ^b   Bath, Philip ^c   Diener, Hans Christoph ^d  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPYRIDAMOLE; TICLOPIDINE; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE;

BLEEDING; CLINICAL TRIAL; DRUG COST; DRUG EFFECT; HEALTH CARE; HUMAN; LETTER; PRIORITY JOURNAL; STROKE; THROMBOCYTE AGGREGATION; TRANSIENT ISCHEMIC ATTACK; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; DRUG COMBINATION; ECONOMICS; NOTE; RISK FACTOR; SWEDEN; DRUG RESISTANCE;

ASPIRIN; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; DRUG COSTS; DRUG THERAPY, COMBINATION; HUMANS; ISCHEMIC ATTACK, TRANSIENT; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; SWEDEN; TICLOPIDINE; DRUG RESISTANCE;

EID: 7644229582     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)17340-6     Document Type: Letter

References (3)

1. H-C Diener J Bogousslavsky LM Brass Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial Lancet 364 2004 331 337
2. K Grundmann K Jaschonek B Kleine J Dichgans H Topka Aspirin non-responder status in patients with recurrent cerebral ischemic attacks J Neurol 250 2003 63 66
3. R Altman HL Luciardi J Muntaner RN Herrera The antithrombotic profile of aspirin: aspirin resistance, or simply failure? Thromb J 2 2004 1 8